Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter May 3, 2018

Circulating soluble RAGE and cell surface RAGE on peripheral blood mononuclear cells in healthy children

  • Alberto García-Salido ORCID logo EMAIL logo , Gustavo Melen , Vanesa Gómez-Piña , Gonzalo Oñoro-Otero , Ana Serrano-González , Juan Casado-Flores and Manuel Ramírez

Abstract

Background:

The receptor for advanced glycation end products (RAGE) has a critical role in the pathogenesis of inflammation. In healthy children, its basal expression on the peripheral blood mononuclear cell (PBMC) and the basal circulating soluble RAGE (sRAGE) levels are unknown. The aim of this study was to describe both.

Methods:

This is a monocentric, observational and descriptive study of samples obtained from healthy children. The RAGE expression on PBMC was analyzed using flow cytometry. The sRAGE values were determined with a specific sandwich enzyme-linked immunosorbent assay (ELISA) kit, later the relation between cellular RAGE and sRAGE was described.

Results:

Forty-three children were included. The median sRAGE level was 849.0±579.0 pg/mL. The RAGE mean fluorescence intensity (MFI) was 1382±506 in monocytes and 792±506 in lymphocytes. There were no differences between genders. A negative correlation was found between sRAGE and RAGE MFI in lymphocytes (r=−0.3; p=0.04).

Conclusions:

We describe for the first time the RAGE surface levels on PBMC in children. It showed a negative correlation with sRAGE. The sRAGE circulating level is lower than the sRAGE level described in adult population or non-healthy children. Our findings should be confirmed in order to apply them as reference values for future investigations.


Corresponding author: Alberto García-Salido, MD, PhD, Pediatric Intensive Care Unit, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo 65, Madrid, Spain, Phone: +34915035900

Acknowledgments

Thanks to all the medical doctors, nurses and auxiliaries from our PICU. Thanks to the nurse-team from the hospital blood-extractions department. Thanks to all the children who participated in this study. Thanks to their caregivers for their patience and comprehension.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This work is original and was funded by “Instituto de Salud Carlos III” (PI11/00066), Funder Id: 10.13039/501100004587.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Mukherjee TK, Mukhopadhyay S, Hoidal JR. Implication of receptor for advanced glycation end product (RAGE) in pulmonary health and pathophysiology. Respir Physiol Neurobiol 2008;162:210–5.10.1016/j.resp.2008.07.001Search in Google Scholar

2. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998–5004.10.1016/S0021-9258(18)42138-2Search in Google Scholar

3. Yerkovich ST, Chang AB, Carroll ML, Petsky HL, Scrivener G, et al. Soluble receptor for advanced glycation end products (sRAGE) is present at high concentrations in the lungs of children and varies with age and the pattern of lung inflammation. Respirology 2012;17:841–6.10.1111/j.1440-1843.2012.02174.xSearch in Google Scholar PubMed

4. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, et al. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993;91:2155–68.10.1172/JCI116442Search in Google Scholar PubMed PubMed Central

5. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993;143:1699–712.Search in Google Scholar

6. Santilli F, Vazzana N, Bucciarelli LG, Davi G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 2009;16:940–52.10.2174/092986709787581888Search in Google Scholar PubMed

7. Xie J, Mendez JD, Mendez-Valenzuela V, Aguilar-Hernandez MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal 2013;25:2185–97.10.1016/j.cellsig.2013.06.013Search in Google Scholar PubMed

8. Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2010;2010:917108.10.1155/2010/917108Search in Google Scholar PubMed PubMed Central

9. Yehya N, Thomas NJ, Meyer NJ, Christie JD, Berg RA, et al. Circulating markers of endothelial and alveolar epithelial dysfunction are associated with mortality in pediatric acute respiratory distress syndrome. Intensive Care Med 2016;42:1137–45.10.1007/s00134-016-4352-1Search in Google Scholar PubMed

10. Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response–the evidence mounts. J Leukoc Biol 2009;86:505–12.10.1189/jlb.0409230Search in Google Scholar PubMed

11. Gonzalez I, Romero J, Rodriguez BL, Perez-Castro R, Rojas A. The immunobiology of the receptor of advanced glycation end-products: trends and challenges. Immunobiology 2013;218:790–7.10.1016/j.imbio.2012.09.005Search in Google Scholar PubMed

12. Garcia-Salido A, Onoro G, Melen GJ, Gomez-Pina V, Serrano-Gonzalez A, et al. Serum sRAGE as a potential biomarker for pediatric bronchiolitis: a pilot study. Lung 2015;193:19–23.10.1007/s00408-014-9663-9Search in Google Scholar PubMed

13. Hergrueter AH, Nguyen K, Owen CA. Matrix metalloproteinases: all the RAGE in the acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2011;300:L512–5.10.1152/ajplung.00023.2011Search in Google Scholar PubMed PubMed Central

14. Drinda S, Franke S, Eidner T, Schmidt C, Ruster C, et al. Decreased RAGE expression in peripheral blood mononuclear cells of patients with rheumatoid arthritis. Clin Exp Rheumatol 2009;27:483–90.Search in Google Scholar

15. Dettoraki A, Gil AP, Spiliotis BE. Association between serum levels of the soluble receptor (sRAGE) for advanced glycation endproducts (AGEs) and their receptor (RAGE) in peripheral blood mononuclear cells of children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009;22:895–904.10.1515/JPEM.2009.22.10.895Search in Google Scholar PubMed

16. Oczypok EA, Perkins TN, Oury TD. All the “RAGE” in lung disease: the receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses. Paediatr Respir Rev 2017;23:40–9.10.1016/j.prrv.2017.03.012Search in Google Scholar PubMed PubMed Central

17. Arce-Mendoza A, Rodriguez-de Ita J, Salinas-Carmona MC, Rosas-Taraco AG. Expression of CD64, CD206, and RAGE in adherent cells of diabetic patients infected with Mycobacterium tuberculosis. Arch Med Res 2008;39:306–11.10.1016/j.arcmed.2007.11.013Search in Google Scholar PubMed

18. Kajikawa M, Nakashima A, Fujimura N, Maruhashi T, Iwamoto Y, et al. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care 2015;38:119–25.10.2337/dc14-1435Search in Google Scholar PubMed

19. Hamasaki MY, Barbeiro HV, de Souza HP, Machado MC, da Silva FP. sRAGE in septic shock: a potential biomarker of mortality. Rev Bras Ter Intensiva 2014;26:392–6.10.5935/0103-507X.20140060Search in Google Scholar PubMed PubMed Central

20. Arabi YM, Dehbi M, Rishu AH, Baturcam E, Kahoul SH, et al. sRAGE in diabetic and non-diabetic critically ill patients: effects of intensive insulin therapy. Crit Care 2011;15:R203.10.1186/cc10420Search in Google Scholar PubMed PubMed Central

21. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda S, et al. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. Clin Biochem 2011;44:601–4.10.1016/j.clinbiochem.2010.12.014Search in Google Scholar PubMed

22. Bopp C, Bierhaus A, Hofer S, Bouchon A, Nawroth PP, et al. Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care 2008;12:201.10.1186/cc6164Search in Google Scholar PubMed PubMed Central

23. Orwoll BE, Sapru A. Biomarkers in pediatric ARDS: future directions. Front Pediatr 2016;4:55.10.3389/fped.2016.00055Search in Google Scholar PubMed PubMed Central

24. Lizotte PP, Hanford LE, Enghild JJ, Nozik-Grayck E, Giles BL, et al. Developmental expression of the receptor for advanced glycation end-products (RAGE) and its response to hyperoxia in the neonatal rat lung. BMC Dev Biol 2007;7:15.10.1186/1471-213X-7-15Search in Google Scholar PubMed PubMed Central

25. Zhao DC, Lu HW, Huang ZH. Association between the receptor for advanced glycation end products gene polymorphisms and cancer risk: a systematic review and meta-analysis. J BUON 2015;20:614–24.Search in Google Scholar

26. Wittwer C, Lehner J, Fersching D, Siegele B, Stoetzer OJ, et al. Methodological and preanalytical evaluation of a RAGE immunoassay. Anticancer Res 2012;32:2075–8.Search in Google Scholar

Received: 2017-12-7
Accepted: 2018-3-26
Published Online: 2018-5-3
Published in Print: 2018-6-27

©2018 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 29.3.2024 from https://www.degruyter.com/document/doi/10.1515/jpem-2017-0512/html
Scroll to top button